The North America Anticoagulant Reversal Drugs Market is expected to witness market growth of 12.5% CAGR during the forecast period (2021-2027).
Doctors recommend Anticoagulant reversal drugs when anticoagulant therapy of a patient should be reversed or neutralized. It mostly occurs when there are bleeding complications and, in such cases, an overdose of anticoagulant drug therapy is given. Oral anticoagulants are used to treat blood-related disorders. It is extremely beneficial in reducing the risk of thromboembolism in AFib patients. The dose of anticoagulants can cause bleeding in AFib patients and they are suggested to take anticoagulant reversal drugs that can prevent excessive bleeding.
Bleeding is sometimes a complicated condition for all anticoagulant therapy. Sometimes, it can lead to chronic debilitating conditions or even death. The possibility of hemorrhage is likely to be associated with the intake of anticoagulation. The risk of bleeding may also be increased with antiplatelet medication, cyclooxygenase type-2 inhibitors, and non-steroidal anti-inflammatory agent treatment. When bleeding is excess and it becomes life-threatening, then anticoagulant reversal drugs are given. It is also used when anticoagulant activity needs to be reversed prior to any surgery. The risk of bleeding versus thromboembolism must be evaluated for each specific patient.
According to the “Global Health and Wellness Report”, in the USA more than 40% of the adult population were suffering from cardiovascular disease in 2018. Moreover, it is also estimated by the heart disease and Stroke Statistics 2019 that 1 out of 3 individuals in the United States is vulnerable to lifetime risk of atrial fibrillation. Thus, the increasing number of cardiovascular diseases is expected to be a big burden on the health care system. It will act as a major factor for the growing demand for anticoagulant reversal drugs in this region and will drive the growth of the market in the coming years. Manufacturers of the anticoagulant reversal drugs market are well aware of the increasing demand and thus navigating their research & development to increase the development of these drugs. These aspects is expected to boost the growth of the market in the region.
The US market dominated the North America Retail Pharmacy Market by Country in 2020, and is expected to continue to be a dominant market till 2027. The Canada market is experiencing a CAGR of 14.9% during (2021-2027). Additionally, The Mexico market is expected to witness a CAGR of 13.9% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By Distribution Channel
By Product Type
By Country
Companies Profiled
Unique Offerings from the Publisher
Doctors recommend Anticoagulant reversal drugs when anticoagulant therapy of a patient should be reversed or neutralized. It mostly occurs when there are bleeding complications and, in such cases, an overdose of anticoagulant drug therapy is given. Oral anticoagulants are used to treat blood-related disorders. It is extremely beneficial in reducing the risk of thromboembolism in AFib patients. The dose of anticoagulants can cause bleeding in AFib patients and they are suggested to take anticoagulant reversal drugs that can prevent excessive bleeding.
Bleeding is sometimes a complicated condition for all anticoagulant therapy. Sometimes, it can lead to chronic debilitating conditions or even death. The possibility of hemorrhage is likely to be associated with the intake of anticoagulation. The risk of bleeding may also be increased with antiplatelet medication, cyclooxygenase type-2 inhibitors, and non-steroidal anti-inflammatory agent treatment. When bleeding is excess and it becomes life-threatening, then anticoagulant reversal drugs are given. It is also used when anticoagulant activity needs to be reversed prior to any surgery. The risk of bleeding versus thromboembolism must be evaluated for each specific patient.
According to the “Global Health and Wellness Report”, in the USA more than 40% of the adult population were suffering from cardiovascular disease in 2018. Moreover, it is also estimated by the heart disease and Stroke Statistics 2019 that 1 out of 3 individuals in the United States is vulnerable to lifetime risk of atrial fibrillation. Thus, the increasing number of cardiovascular diseases is expected to be a big burden on the health care system. It will act as a major factor for the growing demand for anticoagulant reversal drugs in this region and will drive the growth of the market in the coming years. Manufacturers of the anticoagulant reversal drugs market are well aware of the increasing demand and thus navigating their research & development to increase the development of these drugs. These aspects is expected to boost the growth of the market in the region.
The US market dominated the North America Retail Pharmacy Market by Country in 2020, and is expected to continue to be a dominant market till 2027. The Canada market is experiencing a CAGR of 14.9% during (2021-2027). Additionally, The Mexico market is expected to witness a CAGR of 13.9% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product Type
- Idarucizumab
- Andexanet Alfa
- Prothrombin Complex Concentrates
- Phytonadione
- Protamine
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Boehringer Ingelheim International GmbH
- CSL Limited
- Bausch Health Companies, Inc.
- Octapharma AG
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- Dr. Reddy’s Laboratories Ltd.
- AMAG Pharmaceuticals, Inc. (Covis Pharma)
- Alps Pharmaceutical Ind. Co., Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Anticoagulant Reversal Drugs Market, by Distribution Channel
1.4.2 North America Anticoagulant Reversal Drugs Market, by Product Type
1.4.3 North America Anticoagulant Reversal Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition:
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
2.2.3 Opportunities:
Chapter 3. North America Anticoagulant Reversal Drugs Market by Distribution Channel
3.1 North America Hospital Pharmacy Market by Country
3.2 North America Retail Pharmacy Market by Country
3.3 North America Online Pharmacy Market by Country
Chapter 4. North America Anticoagulant Reversal Drugs Market by Product Type
4.1 North America Idarucizumab Market by Country
4.2 North America Andexanet Alfa Market by Country
4.3 North America Prothrombin Complex Concentrates Market by Country
4.4 North America Phytonadione Market by Country
4.5 North America Other Product Type Market by Country
Chapter 5. North America Anticoagulant Reversal Drugs Market by Country
5.1.1 US Anticoagulant Reversal Drugs Market
5.1.2 US Anticoagulant Reversal Drugs Market by Distribution Channel
5.1.3 US Anticoagulant Reversal Drugs Market by Product Type
5.2 Canada Anticoagulant Reversal Drugs Market
5.2.1 Canada Anticoagulant Reversal Drugs Market by Distribution Channel
5.2.2 Canada Anticoagulant Reversal Drugs Market by Product Type
5.3 Mexico Anticoagulant Reversal Drugs Market
5.3.1 Mexico Anticoagulant Reversal Drugs Market by Distribution Channel
5.3.2 Mexico Anticoagulant Reversal Drugs Market by Product Type
5.4 Rest of North America Anticoagulant Reversal Drugs Market
5.4.1 Rest of North America Anticoagulant Reversal Drugs Market by Distribution Channel
5.4.2 Rest of North America Anticoagulant Reversal Drugs Market by Product Type
Chapter 6. Company Profiles
6.1 Boehringer Ingelheim International GmbH
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional & Segmental Analysis
6.1.4 Research & Development Expenses
6.2 CSL Limited
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Bausch Health Companies, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Octapharma AG
6.4.1 Company Overview
6.5 Pfizer, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expense
6.6 Fresenius SE & Co. KGaA
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Approvals:
6.8 Dr. Reddy’s Laboratories Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 AMAG Pharmaceuticals, Inc. (Covis Pharma)
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses
6.9.4 Recent strategies and developments:
6.9.4.1 Partnerships, Collaborations, and Agreements:
6.9.4.2 Acquisition and Mergers:
6.10. Alps Pharmaceutical Ind. Co., Ltd.
6.10.1 Company OverviewList of Tables
Table 1 North America Anticoagulant Reversal Drugs Market, 2017 - 2020, USD Million
Table 2 North America Anticoagulant Reversal Drugs Market, 2021-2027, USD Million
Table 3 North America Anticoagulant Reversal Drugs Market by Distribution Channel, 2017 - 2020, USD Million
Table 4 North America Anticoagulant Reversal Drugs Market by Distribution Channel, 2021-2027, USD Million
Table 5 North America Hospital Pharmacy Market by Country, 2017 - 2020, USD Million
Table 6 North America Hospital Pharmacy Market by Country, 2021-2027, USD Million
Table 7 North America Retail Pharmacy Market by Country, 2017 - 2020, USD Million
Table 8 North America Retail Pharmacy Market by Country, 2021-2027, USD Million
Table 9 North America Online Pharmacy Market by Country, 2017 - 2020, USD Million
Table 10 North America Online Pharmacy Market by Country, 2021-2027, USD Million
Table 11 North America Anticoagulant Reversal Drugs Market by Product Type, 2017 - 2020, USD Million
Table 12 North America Anticoagulant Reversal Drugs Market by Product Type, 2021-2027, USD Million
Table 13 North America Idarucizumab Market by Country, 2017 - 2020, USD Million
Table 14 North America Idarucizumab Market by Country, 2021-2027, USD Million
Table 15 North America Andexanet Alfa Market by Country, 2017 - 2020, USD Million
Table 16 North America Andexanet Alfa Market by Country, 2021-2027, USD Million
Table 17 North America Prothrombin Complex Concentrates Market by Country, 2017 - 2020, USD Million
Table 18 North America Prothrombin Complex Concentrates Market by Country, 2021-2027, USD Million
Table 19 North America Phytonadione Market by Country, 2017 - 2020, USD Million
Table 20 North America Phytonadione Market by Country, 2021-2027, USD Million
Table 21 North America Other Product Type Market by Country, 2017 - 2020, USD Million
Table 22 North America Other Product Type Market by Country, 2021-2027, USD Million
Table 23 North America Anticoagulant Reversal Drugs Market by Country, 2017 - 2020, USD Million
Table 24 North America Anticoagulant Reversal Drugs Market by Country, 2021-2027, USD Million
Table 25 US Anticoagulant Reversal Drugs Market, 2017 - 2020, USD Million
Table 26 US Anticoagulant Reversal Drugs Market, 2021-2027, USD Million
Table 27 US Anticoagulant Reversal Drugs Market by Distribution Channel, 2017 - 2020, USD Million
Table 28 US Anticoagulant Reversal Drugs Market by Distribution Channel, 2021-2027, USD Million
Table 29 US Anticoagulant Reversal Drugs Market by Product Type, 2017 - 2020, USD Million
Table 30 US Anticoagulant Reversal Drugs Market by Product Type, 2021-2027, USD Million
Table 31 Canada Anticoagulant Reversal Drugs Market, 2017 - 2020, USD Million
Table 32 Canada Anticoagulant Reversal Drugs Market, 2021-2027, USD Million
Table 33 Canada Anticoagulant Reversal Drugs Market by Distribution Channel, 2017 - 2020, USD Million
Table 34 Canada Anticoagulant Reversal Drugs Market by Distribution Channel, 2021-2027, USD Million
Table 35 Canada Anticoagulant Reversal Drugs Market by Product Type, 2017 - 2020, USD Million
Table 36 Canada Anticoagulant Reversal Drugs Market by Product Type, 2021-2027, USD Million
Table 37 Mexico Anticoagulant Reversal Drugs Market, 2017 - 2020, USD Million
Table 38 Mexico Anticoagulant Reversal Drugs Market, 2021-2027, USD Million
Table 39 Mexico Anticoagulant Reversal Drugs Market by Distribution Channel, 2017 - 2020, USD Million
Table 40 Mexico Anticoagulant Reversal Drugs Market by Distribution Channel, 2021-2027, USD Million
Table 41 Mexico Anticoagulant Reversal Drugs Market by Product Type, 2017 - 2020, USD Million
Table 42 Mexico Anticoagulant Reversal Drugs Market by Product Type, 2021-2027, USD Million
Table 43 Rest of North America Anticoagulant Reversal Drugs Market, 2017 - 2020, USD Million
Table 44 Rest of North America Anticoagulant Reversal Drugs Market, 2021-2027, USD Million
Table 45 Rest of North America Anticoagulant Reversal Drugs Market by Distribution Channel, 2017 - 2020, USD Million
Table 46 Rest of North America Anticoagulant Reversal Drugs Market by Distribution Channel, 2021-2027, USD Million
Table 47 Rest of North America Anticoagulant Reversal Drugs Market by Product Type, 2017 - 2020, USD Million
Table 48 Rest of North America Anticoagulant Reversal Drugs Market by Product Type, 2021-2027, USD Million
Table 49 Key Information - Boehringer Ingelheim International GmbH
Table 50 key Information - CSL Limited
Table 51 key information - Bausch Health Companies, Inc.
Table 52 Key Information - Octapharma AG
Table 53 Key Information - Pfizer, Inc.
Table 54 key information - Fresenius SE & Co. KGaA
Table 55 key information - Alexion Pharmaceuticals, Inc.
Table 56 key information - Dr. Reddy’s Laboratories Ltd.
Table 57 key information - AMAG Pharmaceuticals, Inc.
Table 58 key information - Alps Pharmaceutical Ind. Co., Ltd.
List of Figures
Fig 1 Methodology for the research
Fig 2 Recent strategies and developments: AMAG Pharmaceuticals, Inc.
Companies Mentioned
- Boehringer Ingelheim International GmbH
- CSL Limited
- Bausch Health Companies, Inc.
- Octapharma AG
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- Dr. Reddy’s Laboratories Ltd.
- AMAG Pharmaceuticals, Inc. (Covis Pharma)
- Alps Pharmaceutical Ind. Co., Ltd.
Methodology
LOADING...
